Progress in premanifest and manifest diagnostics in Huntington's disease;Fortschritte in früh- Und verlaufsdiagnostik bei morbus huntington

Aktuelle Neurologie

Volumn 36, Issue 10, 2009, Pages 506-523

  Saft, C ^c   Koslnskl, C M ^a   Landwehrmeyer, G B ^b  

^a Neurologie Medizinisches   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c ST JOSEF HOSPITAL   (Germany)

Author keywords

Biomarkers; Diagnostics; Huntington's disease

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RACLOPRIDE C 11;

BLOOD ANALYSIS; BRAIN REGION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DISEASE COURSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOTE; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPHYSIOLOGY; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEOMICS; PSYCHIATRIC DIAGNOSIS; RELIABILITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UPREGULATION;

EID: 72449159190     PISSN: 03024350     EISSN: 14389428     Source Type: Journal    
DOI: 10.1055/s-0029-1223409     Document Type: Review

References (251)

1. OMIM 143 100: HUNTINGTON DISEASE; HD
2. Przuntek H, Steigerwald A. Epidemiologic study of Huntington disease in the catchment area of the Wurzburg University Neurologic Clinic with special reference to the Lower Franconia district. Nervenarzt 1987; 58: 424-427
3. Butterfield DA, Oeswein JQ, Markesbery WR. Electron spin resonance study of membrane protein alterations in erythrocytes in Huntington's disease. Nature 1977; 267: 453-455
4. Przuntek H, Kraus PH, Vigenschow H et al. Electron spin resonance of erythrocytes in Huntington's disease. J Neurol 1984; 231: 162-164 (Pubitemid 14095802)
5. Kraus PH, Vigenschow H, Przuntek H. Spin label study of red blood cell membranes in Huntington's disease. Eur Neurol 1986; 25: 61-66 (Pubitemid 16208303)
6. Vigenschow H, Przuntek H, Lawaczeck R. On the exchange of H20/ D20 molecules across membranes of erythrocyte ghosts from patients with Huntington's disease and from normal individuals. J Neurol 1984; 231: 54-55 (Pubitemid 14196249)
7. Schroeder F, Goetz IE, Roberts E. Membrane anomalies in Huntington's disease fibroblasts. J Neurochem 1984; 43: 526-539 (Pubitemid 14093585)
8. Gohlich G, Kuhn W, Hohn H et al. Huntington's disease: biochemical prediction by determination of GABA synthesis of cultured fibroblasts.J Neurol 1984; 231: 50-51
9. Gray PN, Dana SL GABA synthesis by cultured fibroblasts obtained from persons with Huntington's disease. J Neurochem 1979; 33: 985-992
10. Hamel E, Goetz IE, Roberts E. Glutamic acid decarboxylase and gamma-aminobutyric acid in Huntington's disease fibroblasts and other cultured cells, determined by a [3H]muscimol radioreceptor assay. J Neurochem 1981; 37: 1032-1038 (Pubitemid 12209343)
11. Bird ED, Iversen LL. Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia. Brain 1974; 97: 457-472
12. Perry TL, Hansen S, Kloster M. Huntington's chorea. Deficiency of gamma-aminobutyricacid in brain. N EnglJ Med 1973; 288: 337-342
13. Reynolds GP, Pearson SJ. Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain. Neurosci Lett 1987; 78:233-238
14. Spokes EG. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain 1980; 103: 179-210 (Pubitemid 10009481)
15. Kish SJ, Shannak K, Hornykiewicz O. Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum. Ann Neurol 1987; 22: 386-389 (Pubitemid 17137904)
16. Lange H, Thorner G, Hopf A et al. Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sei 1976; 28: 401-425
17. Graveland GA, Williams RS, DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985; 227: 770-773 (Pubitemid 15168268)
18. Martin JB, Gusella JF. Huntington's disease. Pathogenesis and management. N Engl J Med 1986; 315: 1267-1276
19. Seizinger BR, Liebisch DC, Kish SJ et al. Opioid peptides in Huntington's disease: alterations in prodynorphin and proenkephalin system. Brain Res 1986; 378: 405-408 (Pubitemid 16055581)
20. MacMillan JC, Quarrell OWJ. The neurobiology of Huntington's disease. In: Harper PS. Huntington's disease. Second Edition. London: WP Saunders, 1996:317-357
21. Turjanski N, Weeks R, Dolan R et al. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 1995; 118: 689-696
22. Weeks RA, Piccini P, Harding AE et al. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 1996; 40: 49-54
23. Young AB, Greenamyre JT, Hollingsworth Z et al. NMDA receptor losses in putamen from patients with Huntington's disease. Science 1988; 241:981-983
24. Albin RL Young AB, Penney JB et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N engl J Med 1990; 322: 1293-1298
25. Cha JH, Kosinski CM, Kerner JA et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. PNAS (USA) 1998; 95: 6480-6485
26. Kosinski CM, Cha JH, Young AB et al. Huntington chorea. Animal models reveal new hypotheses for pathophysiology and therapy. Nervenarzt 1999; 70: 878-888
27. Gusella JF, Wexler NS, Conneally PM et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983; 306: 234-238
28. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983
29. Andrlch J, Arning L, Wieczorek S et al. Huntington's disease as caused by 34 CAG repeats. Mov Disord 2008
30. Semaka A, Creighton S, Warby S et al. Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clin Genet 2006; 70: 283-294 (Pubitemid 44323391)
31. Nance MA, Myers RH. Juvenile onset Huntington's disease - clinical and research perspectives. Ment Retard Dev Disabil Res Rev 2001 ; 7: 153-157 (Pubitemid 32843805)
32. Leeflang EP, Tavare S, Marjoram P et al. Analysis of germline mutation spectra at the Huntington's disease locus supports a mitotic mutation mechanism. Hum Mol Gen 1999; 8: 173-183 (Pubitemid 29054259)
33. Yoon SR, Dubeau L, deYoung M et al. Huntington disease expansion mutations in humans can occur before meiosis is completed. PNAS (USA) 2003; 100:8834-8838
34. Henley SM, Bates GP, Tabrizi SJ. Biomarkers for neurodegenerative diseases. Curr Opin Neurol 2005; 18: 698-705
35. Shaw LM, Korecka M, Clark CM et al. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 2007; 6: 295-303 (Pubitemid 46505880)
36. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11:136-142 (Pubitemid 26082779)
37. Siesling S, van Vugt JP, Zwlnderman KA et al. Unified Huntington's disease rating scale: a follow up. Mov Disord 1998; 13: 915-919 (Pubitemid 28517668)
38. Snowden JS, Craufurd D, Griffiths HL et al. Awareness of involuntary movements in Huntington disease. Arch Neurol 1998; 55: 801-805 (Pubitemid 28265696)
39. Hoth KF, Paulsen JS, Moser DJ et al. Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol 2007; 29: 365-376
40. Kirkwood SC, Siemers E, Hodes ME et al. Subtle changes among presymptomatic carriers of the Huntington's disease gene. J Neurol Neurosurg Psychiatry 2000; 69: 773-779
41. De Boo G, Tibben A, Hermans J et al. Subtle involuntary movements are not reliable indicators of incipient Huntington's disease. Mov Disord 1998; 13: 96-99 (Pubitemid 28029859)
42. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
43. Hogarth P, Kayson E, Kieburtz K et al. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord 2005; 20: 293-297 (Pubitemid 40613289)
44. Aylward EH. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res bull 2007; 72: 152-158
45. Rosas HD, Feigin AS, Hersch SM. Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. NeuroRx 2004; 1: 263-272
46. Saft C, Lauter T, Kraus PH et al. Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington's disease patients: a case series. BMC Neurology 2006; 6:11
47. Marder K, Zhao H, Myers RH et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 2000; 54: 452-458 (Pubitemid 30078083)
48. Leroi I, Michalon M. Treatment of the psychiatric manifestations of Huntington's disease: a review of the literature. Can J Psychiatry 1998; 43: 933-940 (Pubitemid 29173303)
49. Folstein S, Abbott MH, Chase GA et al. The association of affective disorder with Huntington's disease in a case series and in families. Psychol Med 1983; 13: 537-542
50. Kirkwood SC, Siemers E, Viken R et al. Longitudinal personality changes among presymptomatic Huntington disease gene carriers. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15: 192-197 (Pubitemid 35006774)
51. Craufurd D, ThompsonJC, SnowdenJS. Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14: 219-226
52. Shiwach RS, Norbury CG. A controlled psychiatric study of individuals at risk for Huntington's disease. Br J Psychiatry 1994; 165: 500-505 (Pubitemid 24305959)
53. Paulsen JS, Hayden M, Stout JC et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006; 63: 883-890 (Pubitemid 43882298)
54. Duff K, PaulsenJS, Begllnger LJ et al. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry 2007; 62: 1341-1346 (Pubitemid 350180721)
55. Paulsen JS, Zhao H, Stout JC et al. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 2001; 57: 658-662 (Pubitemid 32782994)
56. Hahn-Barma V, Deweer B, Durr A et al. Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. J Neurol Neurosurg Psychiatry 1998; 64: 172-177 (Pubitemid 28159797)
57. Lyle OE, Gottesman I.I.. Premorbid psychometric indicators of the gene for Huntington's disease. J Consult Clin Psychol 1977; 45: 1011-1022
58. Witjes-Ane MN, Mertens B, van VugtJP et al. Longitudinal evaluation of carriers of Huntington's disease. J Neuropsychiatry Clin Neurosci 2007; 19: 310-317
59. Solomon AC, Stout JC, Johnson SA et al. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 2007; 45: 1767-1776
60. Lemiere J, Decruyenaere M, Evers-Kiebooms G et al. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation - a longitudinal follow-up study. J Neurol 2004; 251: 935-942 (Pubitemid 39119311)
61. Ho AK, Sahakian BJ, Brown RG et al. Profile of cognitive progression in early Huntington's disease. Neurology 2003; 61:1702-1706 (Pubitemid 38020815)
62. Pelnemann A, Schuller S, Pohl C et al. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J Neurol Sci 2005; 239: 11-19 (Pubitemid 41617410)
63. Kassubek J, Juengllng FD, Ecker D et al. Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb Cortex 2005; 15: 846-853
64. Bamford KA, Calne ED, Kido DK et al. A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology 1995; 45: 1867-1873
65. Bamford KA, Caine ED, Kido DK et al. Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study. Neurology 1989; 39: 796-801 (Pubitemid 19150154)
66. Harris GJ, Aylward EH, Peyser CE et al. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch Neurol 1996; 53:316-324
67. Campodonico JR, Aylward E, Codorl AM et al. When does Huntington's disease begin? J Int Neuropsychol Soc 1998; 4: 467-473
68. Jernigan TL Salmon DP, Butters N et al. Cerebral structure on MRI, Part II: Specific changes in Alzheimer's and Huntington's diseases. Biol Psychiatry 1991; 29: 68-81
69. Snowden J, Craufurd D, Griffiths H et al. Longitudinal evaluation of cognitive disorder in Huntington's disease. J Int Neuropsychol Soc 2001; 7: 33-44 (Pubitemid 32177855)
70. Beglinger LJ, Nopoulos PC, Jorge RE et al. White matter volume and cognitive dysfunction in early Huntington's disease. Cogn Behav Neurol 2005; 18: 102-107
71. Aylward EH, Anderson NB, Bylsma FWet al. Frontal lobe volume in patients with Huntington's disease. Neurology 1998; 50: 252-258 (Pubitemid 28106050)
72. Montoya A, Price BH, Menear M et al. Brain imaging and cognitive dysfunctions in Huntington's disease. J Psychiatry Neurosci 2006; 31: 21-29 (Pubitemid 43305307)
73. Feigin A, Ghilardi MF, Huang C et al. Preclinical Huntington's disease: compensatory brain responses during learning. Ann Neurol 2006; 59: 53-59 (Pubitemid 43042871)
74. Hasselbalch SG, Oberg G, Sorensen SA et al. Reduced regional cerebral blood flow in Huntington's disease studied by SPECT. J Neurol Neurosurg Psychiatry 1992; 55: 1018-1023
75. Tanahashi N, Meyer JS, Ishikawa Yet al. Cerebral blood flow and cognitive testing correlate in Huntington's disease. Arch Neurol 1985; 42: 1169-1175
76. Berent S, Giordani B, Lehtinen S et al. Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function. Ann Neurol 1988; 23: 541-546
77. Kuwert T, Lange HW, Langen KJ et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 1990; 113: 1405-1423 (Pubitemid 20385921)
78. Brandt J, Folstein SE, Wong DF et al. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. J Neurol Neurosurg Psychiatry 1990; 2: 20-27 (Pubitemid 20125840)
79. Backman L Robins-Wahlin TB, Lundin A et al. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 1997; 120): 2207-2217
80. Ginovart N, Lundin A, Farde L et al. PET study of the pre- and postsynaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997; 120: 503-514 (Pubitemid 27153642)
81. Lawrence AD, Weeks RA, Brooks DJ et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain 1998; 121: 1343-1355
82. Rosas HD, Salat DH, Lee SY et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008; 131: 1057-1068
83. Wolf RC, Sambataro F, Vasic N et al. Altered frontostriatal coupling in pre-manifest Huntington's disease: effects of increasing cognitive load. Eur J Neurol 2008; 15: 1180-1190
84. Wolf RC, Sambataro F, Vasic N et al. Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease. Exp Neurol 2008; 213: 137-144
85. Sax DS, Powsner R, Kim A et al. Evidence of cortical metabolic dysfunction in early Huntington's disease by single-photon-emission computed tomography. Mov Disord 1996; 11: 671-677 (Pubitemid 26381937)
86. Wolf RC, Vasic N, Schonfeldt-Lecuona C et al. Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. Brain 2007; 130: 2845-2857 (Pubitemid 350033962)
87. Paulsen JS. Functional imaging in Huntington's disease. Exp Neurol 2009; 216: 272-277
88. Brinkman RR, Mezei MM, Theilmann J et al. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997; 60: 1202-1210 (Pubitemid 27194105)
89. Wexler NS, Lorimer J, Porter J et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. PNAS (USA) 2004; 101: 3498-3503 (Pubitemid 38338224)
90. Langbehn DR, Brinkman RR, Falush D et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004; 65: 267-277
91. Harris GJ, Codorl AM, Lewis RF et al. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999; 122: 1667-1678
92. Aylward EH, Sparks BF, Field KM et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004; 63: 66-72
93. Ranen NG, Stine OC, Abbott MH et al. Anticipation and instability of IT15 (CAG)n repeats in parent-offspring pairs with Huntington disease. AmJ Hum Genet 1995; 57: 593-602
94. Andresen JM, Gayan J, Cherny SS et al. Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. J Med Genet 2007; 44: 44-50 (Pubitemid 46142838)
95. Arning L Monte D, Hansen W et al. ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease. J Mol Med 2008; 86: 485-490
96. Arning L Kraus PH, Valentin S et al. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics 2005; 6: 25-28 (Pubitemid 40394827)
97. Arning L, Saft C, Wieczorek S et al. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Gen 2007; 122: 175-182 (Pubitemid 47241782)
98. Saft C, Andrich JE, Brune N et al. Apolipoprotein E genotypes do not influence the age of onset in Huntington's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1692-1696 (Pubitemid 39611467)
99. Weydt P, Soyal SM, Gellera C et al. The gene coding for PGC-lalpha modifies age at onset in Huntington's Disease. Mol Neurodegener 2009; 4: 3
100. Taherzadeh-Fard E, Saft C, Andrlch J et al. PGC-lalpha as modifier of onset age in Huntington disease. Mol Neurodegener 2009; 4: 10
101. Penney JB Jr, Vonsattel JP, MacDonald ME et al. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997; 41: 689-692
102. Sanchez-Pernaute R, Kunig G, del Barrio Alba A et al. Bradykinesia in early Huntington's disease. Neurology 2000; 54: 119-125
103. Ravina B, Romer M, Constantlnescu R et al. The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord 2008; 23: 1223-1227
104. Rosenbiatt A, Liang KY, Zhou H et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 2006; 66: 1016-1020
105. Berardelli A, Noth J, Thompson PD et al. Pathophysiology of chorea and bradykinesia in Huntington's disease. Mov Disord 1999; 14: 398-403
106. Noth J, Friedemann HH, Podoll K et al. Absence of long latency reflexes to imposed finger displacements in patients with Huntington's disease. Neurosci Lett 1983; 35: 97-100 (Pubitemid 13186958)
107. Noth J, Engel L Friedemann HH et al. Evoked potentials in patients with Huntington's disease and their offspring. I. Somatosensory evoked potentials. Electroencephalogr Clin Neurophysiol 1984; 59: 134-141
108. Kuwert T, Noth J, Scholz D et al. Comparison of somatosensory evoked potentials with striatal glucose consumption measured by positron emission tomography in the early diagnosis of Huntington's disease. Mov Disord 1993; 8: 98-106 (Pubitemid 23039239)
109. Ellenberger C Jr, Petro DJ, Ziegler SB. The visually evoked potential in Huntington disease. Neurology 1978; 28: 95-97 (Pubitemid 8272525)
110. Hennerid M, Homberg V, Lange HW. Evoked potentials in patients with Huntington's disease and their offspring. II. Visual evoked potentials. Electroencephalogr Clin Neurophysiol 1985; 62: 167-176
111. Beenen N, Buttner U, Lange HW. The diagnostic value of eye movement recordings in patients with Huntington's disease and their offspring. Electroencephalogr Clin Neurophysiol 1986; 63: 119-127 (Pubitemid 16154679)
112. Beste C, Saft C, Andrlch J et al. Error processing in Huntington's disease. PLoS ONE 2006; 1: e86
113. Beste C, Saft C, Andrlch J et al. Response inhibition in Huntington's disease - a study using ERPs and sLORETA. Neuropsychologia 2008; 46: 1290-1297
114. Beste C, Saft C, Andrich J et al. Time processing in Huntington's disease: a group-control study. PLoS ONE 2007; 2: e1263
115. Beste C, Saft C, YordanovaJ et al. Functional compensation or pathology in cortico-subcortical interactions in preclinical Huntington's disease? Neuropsychologia 2007; 45: 2922-2930
116. Beste C, Saft C, Gunturkun O et al. Increased cognitive functioning in symptomatic Huntington's disease as revealed by behavioral and event-related potential indices of auditory sensory memory and attention. J Neurosci 2008; 28: 11695-11702
117. Hefter H, Homberg V, Lange HW et al. Impairment of rapid movement in Huntington's disease. Brain 1987; 110: 585-612 (Pubitemid 17081163)
118. Garda Ruiz PJ, Hernandez J, Cantarero S et al. Bradykinesia in Huntington's disease. A prospective, follow-up study. J Neurol 2002; 249: 437-440 (Pubitemid 34304618)
119. van Vugt JP, Piet KK, Vink LJ et al. Objective assessment of motor slowness in Huntington's disease: clinical correlates and 2-year follow-up. Mov Disord 2004; 19: 285-297
120. van Vugt JP, Siesling S, Piet KK et al. Quantitative assessment of daytime motor activity provides a responsive measure of functional decline in patients with Huntington's disease. Mov Disord 2001; 16: 481-488 (Pubitemid 36041152)
121. Reilmann R, Kirsten F, Quinn L et al. Objective assessment of progression in Huntington's disease: a 3-year follow-up study. Neurology 2001; 57: 920-924 (Pubitemid 32845525)
122. Rao AK, Quinn L Marder KS. Reliability of spatiotemporal gait outcome measures in Huntington's disease. Mov Disord 2005; 20: 1033-1037
123. Saft C, Andrich J, Meisel NM et al. Assessment of complex movements reflects dysfunction in Huntington's disease. J Neurol 2003; 250: 1469-1474 (Pubitemid 38121845)
124. Saft C, Andrich J, Meisel NM et al. Assessment of simple movements reflects impairment in Huntington's disease. Mov Disord 2006; 21: 1208-1212 (Pubitemid 44336609)
125. Saft C, Andrich J, Meisel NM et al. Congruent deterioration of complex and simple movements in patients with Huntington's disease. J Neural Transm 2004; 68: 97-104 (Pubitemid 39215442)
126. Andrich J, Saft C, Ostholt N et al. Assessment of simple movements and progression of Huntington's disease. J Neurol Neurosurg Psychiatry 2007; 78: 405-407 (Pubitemid 46580553)
127. Andrich J, Saft C, Ostholt N et al. Complex movement behaviour and progression of Huntington's disease. Neurosci Lett 2007; 416: 272-274 (Pubitemid 46483870)
128. Hinton SC, Paulsen JS, Hoffmann RG et al. Motor timing variability increases in preclinical Huntington's disease patients as estimated onset of motor symptoms approaches. J Int Neuropsychol Soc 2007; 13: 539-543
129. Michell AW, Goodman AO, Silva AH et al. Hand tapping: A simple, reproducible, objective marker of motor dysfunction in Huntington's disease. J Neurol 2008
130. Paulsen JS, Langbehn DR, Stout JC et al. Detection of Huntington's disease decades before diagnosis: The Predict HD study. J Neurol Neurosurg Psychiatry 2007
131. Smith MA, Brandt J, Shadmehr R. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature 2000; 403: 544-549 (Pubitemid 30082199)
132. Blekher T, Johnson SA, Marshall J et al. Saccades in presymptomatic and early stages of Huntington disease. Neurology 2006; 67: 394-399
133. Hicks SL Robert MP, Golding CV et al. Oculomotor deficits indicate the progression of Huntington's disease. Prog Brain Res 2008; 171: 555-558
134. Becker W, Jurgens R, KassubekJ et al. Eye-head coordination in moderately affected Huntington's Disease patients: do head movements facilitate gaze shifts? Exp Brain Res 2009; 192: 97-112
135. Wild EJ, Tabrizi SJ. Predict-HD and the future of therapeutic trials. Lancet Neurol 2006; 5: 724-725
136. Huckman MS, Fox J, TopelJ. The validity of criteria for the evaluation of cerebral atrophy by computed tomography. Radiology 1975; 116: 85-92
137. Stober T, Wussow W, Schimrigk K. Bicaudate diameter - the most specific and simple CT parameter in the diagnosis of Huntington's disease. Neuroradiology 1984; 26: 25-28 (Pubitemid 14211882)
138. Aylward EH, Codorl AM, Barta PE et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996; 53: 1293-1296
139. Aylward EH, Codorl AM, Rosenblatt A et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000; 15: 552-560
140. Aylward EH, Brandt J, Codorl AM et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994; 44: 823-828
141. Kipps CM, Duggins AJ, Mahant N et al. Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry 2005; 76: 650-655 (Pubitemid 40569674)
142. Thieben MJ, Duggins AJ, Good CD et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002; 125: 1815-1828
143. Rosas HD, Hevelone ND, Zaleta AK et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005; 65: 745-747
144. Nopoulos P, Magnotta VA, Mikos A et al. Morphology of the cerebral cortex in preclinical Huntington's disease. Am J Psychiatry 2007; 164: 1428-1434 (Pubitemid 47461144)
145. Paulsen JS, Magnotta VA, Mikos AE et al. Brain structure in preclinical Huntington's disease. Biol Psychiatry 2006; 59: 57-63
146. Rosas HD, Tuch DS, Hevelone ND et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord 2006; 21:1317-1325
147. Reading SA, Yassa MA, Bakker A et al. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res 2005; 140: 55-62 (Pubitemid 41443496)
148. Kloppel S, Draganski B, Golding CVet al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 2008; 131: 196-204
149. Kloppel S, Chu C, Tan GC et al. Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurology 2009; 72: 426-431
150. Aylward EH, Li Q, Stine OC et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997; 48: 394-399 (Pubitemid 27087610)
151. Brandt J, Bylsma FW, Aylward EH et al. Impaired source memory in Huntington's disease and its relation to basal ganglia atrophy. J Clin Exp Neuropsychol 1995; 17: 868-877 (Pubitemid 26020988)
152. Harris GJ, Pearlson GD, Peyser CE et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann Neurol 1992; 31: 69-75
153. Rosas HD, Koroshetz WJ, Chen YI et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003; 60: 1615-1620
154. Ruocco HH, Lopes-Cendes I, Li LM et al. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. Brazilian Journal of Medical and Biological Research-Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica [et al] 2006; 39: 1129-1136 (Pubitemid 44241274)
155. Starkstein SE, Brandt J, Bylsma F et al. Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study. Neuroradiology 1992; 34: 487-489
156. Bohanna I, Georgiou-Karistianis N, Hannan AJ et al. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res Rev 2008
157. Muhlau M, Weindi A, Wohlschlager AM et al. Voxel-based morphometry indicates relative preservation of the limbic prefrontal cortex in early Huntington disease. J Neural Transm 2007; 114: 367-372 (Pubitemid 46328656)
158. Mascalchi M, Lolli F, Della Nave R et al. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology 2004; 232: 867-873
159. Jech R, Klempir J, Vymazal J et al. Variation of selective gray and white matter atrophy in Huntington's disease. Mov Disord 2007; 22: 1783-1789 (Pubitemid 47597603)
160. Vonsattel JP, Myers RH, Stevens TJ et al. Neuropathological classification of Huntington's disease. J Neuropath Exp Neurol 1985; 44: 559-577
161. Kassubek J, Juengling FD, Kioschies T et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 2004; 75: 213-220 (Pubitemid 38183526)
162. Douaud G, Gaura V, Ribeiro MJ et al. Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study. Neurolmage 2006; 32: 1562-1575 (Pubitemid 44332291)
163. Muhlau M, Wohlschlager AM, Gaser Cet al. Voxel-based morphometry in individual patients: a pilot study in early Huntington disease. Ajnr 2009; 30: 539-543
164. Douaud G, Behrens TE, Poupon Cet al. In vivo evidence for the selective subcortical degeneration in Huntington's disease. Neurolmage 2009; 46: 958-966
165. Henley SM, Frost C, MacManus DG et al. Increased rate of whole-brain atrophy over 6 months in early Huntington disease. Neurology 2006; 67: 694-696
166. Henley SM, Wild EJ, Hobbs NZ et al. Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord 2009; 24: 932-936
167. KassubekJ, Landwehrmeyer GB, Ecker D et al. Global cerebral atrophy in early stages of Huntington's disease: quantitative MRI study. Neuroreport 2004; 15: 363-365
168. Muhlau M, Gaser C, Wohlschlager AM et al. Striatal gray matter loss in Huntington's disease is leftward biased. Mov Disord 2007; 22:1169-1173
169. Halliday GM, McRitchie DA, Macdonald V et al. Regional specificity of brain atrophy in Huntington's disease. Exp Neurol 1998; 154: 663-672
170. Rosas HD, Liu AK, Hersch S et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002; 58: 695-701 (Pubitemid 34211546)
171. Seppl K, Schocke MF, Mair KJ et al. Diffusion-weighted imaging in Huntington's disease. Mov Disord 2006; 21: 1043-1047
172. Weaver KE, Richards TL Liang O et al. Longitudinal diffusion tensor imaging in Huntington's Disease. Exp Neurol 2009; 216: 525-529
173. Vandenberghe W, Demaerel P, Dom R et al. Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease. J Neurol 2009; 256: 109-114
174. Alexander GE, DeLong MR, Strick PL Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 1986; 9: 357-381
175. Tobin AJ, Signer ER. Huntington's disease: the challenge for cell biologists. Trends Cell Biol 2000; 10: 531-536
176. Taylor-Robinson SD, Weeks RA, Bryant DJ et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord 1996; 11: 167-173
177. Jenkins BG, Rosas HD, Chen YC et al. IH NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998; 50: 1357-1365
178. Martin WR, Wieler M, Hanstock CC. Is brain lactate increased in Huntington's disease? J Neurol Sci 2007; 263: 70-74
179. Harms L, Meierkord H, Timm G et al. Decreased N-acetyl-aspartate/ choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry 1997; 62: 27-30 (Pubitemid 27047437)
180. Hoang TQ, Bluml S, Dubowitz DJ et al. Quantitative proton-decoupled 31P MRS and IH MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 1998; 50: 1033-1040
181. Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A et al. Clinical correlation of striatal IH MRS changes in Huntington's disease. Neurology 1999; 53: 806-812
182. Bender A, Auer DP, Merl T et al. Creatine supplementation lowers brain glutamate levels in Huntington's disease. J Neurol 2005; 252: 36-41 (Pubitemid 40179016)
183. Tabrizi SJ, Blamire AM, Manners DN et al. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 2005; 64: 1655-1656
184. Tabrizi SJ, Blamire AM, Manners DN et al. Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology 2003; 61: 141-142
185. Reynolds NC Jr, Prost RW, Mark LP. Heterogeneity in IH-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res 2005; 1031: 82-89
186. Lodi R, Schapira AH, Manners Detal. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000; 48: 72-76 (Pubitemid 30432433)
187. Saft C, Zange J, Andrich J et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 2005; 20: 674-679 (Pubitemid 41051778)
188. van Oostrom JC, Sijens PE, Roos RA et al. 1H magnetic resonance spectroscopy in preclinical Huntington disease. Brain Res 2007; 1168: 67-71 (Pubitemid 47320622)
189. Hennenlotter A, Schroeder U, Erhard P et al. Neural correlates associated with impaired disgust processing in pre-symptomatic Huntington's disease. Brain 2004; 127: 1446-1453
190. Sprengelmeyer R, YoungAW, Calder AJ et al. Loss of disgust. Perception of faces and emotions in Huntington's disease. Brain 1996; 119: 147-1665
191. Reading SA, DziornyAC, Peroutka LA et al. Functional brain changes in presymptomatic Huntington's disease. Ann Neurol 2004; 55: 879-883
192. Paulsen JS, Zimbelman JL Hinton SC et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's disease. AJNR 2004; 25: 1715-1721
193. Zimbelman JL Paulsen JS, Mikos A et al. fMRI detection of early neural dysfunction in preclinical Huntington's disease. J Int Neuropsychol Soc 2007; 13: 758-769 (Pubitemid 47299445)
194. Saft C, Schuttke A, Beste C et al. fMRI reveals altered auditory processing in manifest and premanifest Huntington's disease. Neuropsychologia 2008; 46: 1279-1289
195. Aron AR, Schlaghecken F, Fletcher PC et al. Inhibition of subliminally primed responses is mediated by the caudate and thalamus: evidence from functional MRI and Huntington's disease. Brain 2003; 126: 713-723 (Pubitemid 36240871)
196. Voermans NC, Petersson KM, Daudey L et al. Interaction between the human hippocampus and the caudate nucleus during route recognition. Neuron 2004; 43: 427-435
197. Gavazzi C, Nave RD, Petralli R et al. Combining functional and structural brain magnetic resonance imaging in Huntington disease. J Cornput Assist Tomogr 2007; 31: 574-580 (Pubitemid 47457673)
198. Dierks T, Linden DE, Hertel A et al. Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: a case study of parietal lobe function in a patient with Huntington's disease. Psychiatry Res 1999; 90: 67-75
199. Georgiou-Karistianis N, Sritharan A, Farrow M et al. Increased cortical recruitment in Huntington's disease using a Simon task. Neuropsychologia 2007; 45: 1791-1800
200. Clark VP, Lai S, Deckel AW. Altered functional MRI responses in Huntington's disease. Neuroreport 2002; 13:703-706 (Pubitemid 34293495)
201. Kim JS, Reading SA, Brashers-Krug T et al. Functional MRI study of a serial reaction time task in Huntington's disease. Psychiatry Res 2004; 131: 23-30
202. Thiruvady DR, Georglou-Karlstlanls N, Egan GF et al. Functional connectivity of the prefrontal cortex in Huntington's disease. J Neurol Neurosurg Psychiatry 2007; 78: 127-133 (Pubitemid 46220207)
203. Beste C, Schuttke A, Konrád C et al. Functional Connectivity during auditory processing in Huntington's disease. J Psychphysiol 2008; 22: 195-201
204. Saft C, Schutte A, Beste C et al. Altered auditory sensory processing in premanifest Huntington's disease: Are there different phases in premanifest Huntington's disease? J Neurol Neurosurg Psychiatry 2008; 79: All
205. Kuhi DE, Phelps ME, Markham CH et al. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann Neurol 1982; 12: 425-434
206. Kuwert T, Ganslandt T, Jansen P et al. Influence of size of regions of interest on PET evaluation of caudate glucose consumption. J Comput Assist Tomogr 1992; 16: 789-794
207. Kuwert T, Lange HW, Boecker H et al. Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease. J Neurol 1993; 241: 31-36 (Pubitemid 23342424)
208. Young AB, Penney JB, Starosta-Rubinstein S et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 1986; 20: 296-303 (Pubitemid 16018512)
209. Young AB, Penney JB, Starosta-Rubinstein S et al. Normal caudate glucose metabolism in persons at risk for Huntington's disease. Arch Neurol 1987; 44: 254-257
210. Grafton ST, Mazziotta JC, Pahl JJ et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol 1992; 49: 1161-1167
211. Hagglund J, Aqullonius SM, Eckernas SA et al. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11 C-N-methyl-spiperone. Acta Neurol Scand 1987; 75: 87-94
212. Pavese N, Andrews TC, Brooks DJ et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 2003; 126: 1127-1135 (Pubitemid 36522955)
213. Antonini A, Leenders KL, Spiegel R et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996; 119: 2085-2095
214. van Oostrom JC, Magulre RP, Verschuuren-Bemelmans CC et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology 2005; 65: 941-943
215. Bartenstein P, Weindl A, Spiegel S et al. Central motor processing in Huntington's disease. A PET study. Brain 1997; 120: 1553-1567
216. Boecker H, Ceballos-Baumann A, Bartenstein P et al. Sensory processing in Parkinson's and Huntington's disease: investigations with 3D H(2)(15)0-PET. Brain 1999; 122: 1651-1665
217. Pavese N, Gerhard A, Tai YF et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006; 66: 1638-1643 (Pubitemid 43964614)
218. Tai YF, Pavese N, Gerhard A et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007; 130: 1759-1766 (Pubitemid 47343790)
219. Feigin A, Tang C, Ma Y et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 2007; 130: 2858-2867 (Pubitemid 350033965)
220. Boroveckl F, Lovreclc L Zhou J et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. PNAS (USA) 2005; 102: 11023-11028
221. Runne H, Kuhn A, Wild EJ et al. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. PNAS (USA) 2007; 104: 14424-14429 (Pubitemid 350003277)
222. Benn CL, Fox H, Bates GP. Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease. Mol Neurodegener 2008; 3: 17
223. Strand AD, Aragakl AK, Shaw D et al. Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Gen 2005; 14: 1863-1876 (Pubitemid 41418057)
224. Zabel C, Chamrad DC, Priller J et al. Alterations in the mouse and human proteome caused by Huntington's disease. Mol Cell Proteomics 2002; 1: 366-375
225. Petersen A, Gil J, Maat-Schleman ML et al. Orexin loss in Huntington's disease. Hum Mol Gen 2005; 14: 39-47
226. Bjorkqvlst M, Petersen A, Nielsen J et al. Cerebrospinal fluid levels of orexin - A are not a clinically useful biomarker for Huntington disease. Clin Genet 2006; 70: 78-79
227. Aziz NA, van der Burg JM, Landwehrmeyer GB et al. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008; 71: 1506-1513
228. Valenza M, CarrollJB, Leonl V et al. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum Mol Gen 2007; 16: 2187-2198 (Pubitemid 47354901)
229. Valenza M, Leoni V, Tarditi A et al. Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2007; 28: 133-142 (Pubitemid 47429978)
230. Leoni V, Mariotti C, Tabrizi SJ et al. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 2008; 131: 2851-2859
231. Tsang TM, Woodman B, McLoughlin GA et al. Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS IH NMR spectroscopy. J Proteome Res 2006; 5: 483-492 (Pubitemid 43364087)
232. Bjorkqvist M, Petersen A, Bacos K et al. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum Mol Gen 2006; 15: 1713-1721 (Pubitemid 43904837)
233. Aziz NA, Pijl H, Frolich M et al. Increased hypothalamic-pituitary- adrenal axis activity in Huntington's disease. J Clin Endocrinol Metab 2009; 94: 1223-1228
234. Saleh N, Moutereau S, Durr A et al. Neuroendocrine disturbances in Huntington's disease. PLoS ONE 2009; 4: e4962
235. Politis M, Pavese N, Tai YF et al. Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 2008; 131: 2860-2869
236. Weydt P, Pineda W, Torrence AE et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 2006; 4: 349-362 (Pubitemid 44645069)
237. Bjorkqvist M, Leavitt BR, Nielsen JE et al. Cocaine- and amphetamineregulated transcript is increased in Huntington disease. Mov Disord 2007; 22: 1952-1954
238. Mollenhauer B, Bibl M, Esselmann H et al. Selective reduction of amyloid beta42 discriminates Alzheimer's disease from Huntington's disease: indication for distinct pathological events in amyloid beta peptide aggregation. J Neurol Neurosurg Psychiatry 2006; 77: 1201-1203 (Pubitemid 44453264)
239. Hamacher M, Stephan C, Hardt T et al. Applications in brain proteomies: 8(th) HUPO Brain Proteome Project Workshop 7 October 2007, Seoul, Korea. Proteomics 2008; 8: 1750-1753
240. Fang Q, Strand A, Law Wet al. Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. MoI Cell Proteomics 2009; 8: 451-466
241. DalrympleA, Wild EJ, Joubert R et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 2007; 6: 2833-2840 (Pubitemid 47122377)
242. LebihuberF, Walli J, Jellinger K et al. Activated immune system in patients with Huntington's disease. Clin Chem Lab Med 1998; 36: 747-750 (Pubitemid 28521525)
243. Singhrao SK, Neal JW, Morgan BP et al. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp Neurol 1999; 159: 362-376
244. Bjorkqvlst M, Wild EJ, Thiele J et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.J Exp Med 2008; 205: 1869-1877
245. Barrios FA, Gonzalez L, Favila R et al. Olfaction and neurodegeneration in HD. Neuroreport 2007; 18: 73-76
246. Hamacher M, Stephan C, Elsenacher M et al. Maintaining standardization: an update of the HUPO Brain Proteome Project. Expert Rev Proteomics 2008; 5: 165-173 (Pubitemid 351670923)
247. Myers T, Law W, Eng JK et al. Installation and use of the Computational Proteomics Analysis System (CPAS). Current protocols in bioinformatics 2007; Chapter 13: Unit 13-15
248. Luthi-Carter R, Hanson SA, Strand AD et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Gen 2002; 11: 1911-1926 (Pubitemid 34928255)
249. Tarditi A, Camurri A, Varani K et al. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol Dis 2006; 23: 44-53 (Pubitemid 43903630)
250. World Federation of Neurology: Research Committee. Research Group on Huntington's chorea.. Ethical issues policy statement on Huntington's disease molecular genetics predictive test. J Neurol Sci 1989; 94: 327-332
251. Went L Ethical issues policy statement on Huntington's disease molecular genetics predictive test. International Huntington Association. World Federation of Neurology. J Med Genet 1990; 27: 34-38